XML 224 R39.htm IDEA: XBRL DOCUMENT v3.22.4

Revenue recognition (Tables)

12 Months Ended

Dec. 31, 2022

Revenue from Contract with Customer [Abstract]

Summary of Disaggregation of Revenue

The Company's revenues disaggregated by the major sources were as follows:

			Year Ended December 31,
			2022																		2021																		2020
			USG						Non-USG						Total						USG						Non-USG						Total						USG						Non-USG						Total
Product sales			$	445.4					$	520.8					$	966.2					$	530.0					$	493.9					$	1,023.9					$	626.0					$	363.8					$	989.8
CDMO:
Services			—						108.4						108.4						—						334.9						334.9						—						166.7						166.7
Leases			—						4.9						4.9						237.6						62.1						299.7						253.3						30.5						283.8
Total CDMO			—						113.3						113.3						237.6						397.0						634.6						253.3						197.2						450.5
Contracts and grants			37.2						4.2						41.4						130.2						4.0						134.2						109.2						5.9						115.1
Total revenues			$	482.6					$	638.3					$	1,120.9					$	897.8					$	894.9					$	1,792.7					$	988.5					$	566.9					$	1,555.4

Schedules of Concentration of Risk, by Risk Factor

For the years ended December 31, 2022, 2021 and 2020, the Company's product sales from Anthrax Vaccines, Nasal Naloxone products, TEMBEXA, ACAM2000 and Other products as a percentage of total product sales were as follows:

			Year Ended December 31,
			2022						2021						2020
% of product sales:
Anthrax vaccines			28		%				25		%				38		%
Nasal naloxone products			39		%				43		%				31		%
TEMBEXA			12		%				—		%				—		%
ACAM2000			7		%				20		%				20		%
Other products			14		%				12		%				11		%

Summary of Deferred Revenue Contract Liabilities

The following table presents the roll forward of the contract liabilities:

			Contract Liabilities
Balance at December 31, 2020			$	100.1
Deferral of revenue			279.7
Revenue recognized			(363.4)
Balance at December 31, 2021			$	16.4
Deferral of revenue			38.9
Revenue recognized			(23.6)
Balance at December 31, 2022			$	31.7

Schedule of Accounts Receivable, Net

Accounts receivable including unbilled accounts receivable contract assets consist of the following:

			December 31,
			2022						2021
Accounts receivable:
Billed			$	102.7					$	228.1
Unbilled			56.4						49.8
Allowance for expected credit losses			(0.7)						(3.2)
Accounts receivable, net			$	158.4					$	274.7

X

- Definition

Schedule of Accounts Receivable, Net [Table Text Block]

+ References

No definition available.

+ Details

Name:	ebs_ScheduleOfAccountsReceivableNetTableTextBlock
Namespace Prefix:	ebs_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045

+ Details

Name:	us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 16
-URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592

+ Details

Name:	us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration